본문 바로가기
KERD
논문KCI 등재

급성관상동맥 증후군 치료를 위한 국내·외 항혈소판제 약물요법 가이드라인 비교 연구

A Comparative Study the USA, Europe and Korea Guidelines of Antiplatelet Therapy for Patients with Acute Coronary Syndrome

이채원|백인환|정은주
한국임상약학회 (Korean College Of Clinical Pharmacy)|2015.09|한국임상약학회지 (Korean Journal of Clinical Pharmacy)|제25권 제3호|pp. 200-208

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

guidelineKSCESCacute coronary syndromeantiplatelet therapyACC/AHA
주제분류약학

초록

Objective: Patients with acute coronary syndrome (ACS) are typically managed with dual antiplatelet therapy of acetylsalicylic acid (aspirin) and P2Y12 receptor inhibitor. In this study, we discussed current and previous antiplatelet therapy guidelines and compared with guidelines of the USA (ACC/AHA), Europe (ESC) and Korea (KSC). Method: This study investigated from ACC/AHA Joint Guidelines (the USA), ESC Clinical Practice Guidelines (Europe) and Korea Society of Interventional Cardiology (Korea) web site, respectively. Results: It is significant that difference between the current and the previous guidelines was integration of terminology from clopidogrel to P2Y12 receptor inhibitors since prasugrel and ticagrelor, new antiplatelet drugs, has been added. The other difference was all three guidelines has differences in dose of aspirin. The most notable difference was class of recommendation (COR) in P2Y12 receptor inhibitors. ACC/AHA and Korean guidelines recommend clopidogrel, prasugrel, and ticagrelor with COR IB; whereas, ESC recommend prasugrel and ticagrelor with IB which is higher than clopidogrel with IC. Conclusion: This research addresses important movement to revise the Korean existing guideline recommendations. New Korean antiplatelet therapy guideline should be avoiding obvious differences in ACC/AHA and ESC guidelines and harmonizing international guidelines.

Abstract

Objective: Patients with acute coronary syndrome (ACS) are typically managed with dual antiplatelet therapy of acetylsalicylic acid (aspirin) and P2Y12 receptor inhibitor. In this study, we discussed current and previous antiplatelet therapy guidelines and compared with guidelines of the USA (ACC/AHA), Europe (ESC) and Korea (KSC). Method: This study investigated from ACC/AHA Joint Guidelines (the USA), ESC Clinical Practice Guidelines (Europe) and Korea Society of Interventional Cardiology (Korea) web site, respectively. Results: It is significant that difference between the current and the previous guidelines was integration of terminology from clopidogrel to P2Y12 receptor inhibitors since prasugrel and ticagrelor, new antiplatelet drugs, has been added. The other difference was all three guidelines has differences in dose of aspirin. The most notable difference was class of recommendation (COR) in P2Y12 receptor inhibitors. ACC/AHA and Korean guidelines recommend clopidogrel, prasugrel, and ticagrelor with COR IB; whereas, ESC recommend prasugrel and ticagrelor with IB which is higher than clopidogrel with IC. Conclusion: This research addresses important movement to revise the Korean existing guideline recommendations. New Korean antiplatelet therapy guideline should be avoiding obvious differences in ACC/AHA and ESC guidelines and harmonizing international guidelines.

참고문헌 (57)

  1. Overbaugh., "Acute coronary syndrome", AJN, 109(5), pp.42~52 (2009)
  2. Yun DD., "Acute coronary syndromes", Cardiology, 88, pp.223~237 (1997)
  3. Park SJ, "Acute coronary syndrome", Korean Circulation J, 28(12), pp.2066~2075 (1998)
  4. Molife C., "Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor", Med Econ, in press
  5. Fanari Z., "Cost effectiveness of antiplatelet and antithrombotic therapy in the setting of acute coronary syndrome: current perspective and literature review", Am J Cardiovasc Drugs, in press
  6. Kim J., "Economic burden of acute coronary syndrome in South Korea : a national survey", BMC Cardiovasc Disord, 13(55), pp.1~8 (2013)
  7. Korsnes JS., "Health care resource utilization and costs associated with nonfatal major adverse cardiovascular events", J Manag Care Spec Pharm, 21(6), pp.443~450 (2015)
  8. Anderson JL., "ACC", AHA 2007 Guidelines for the management of patients with unstable angina, American heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina, pp.non-ST-elevation myocardial infarction), Circulation[DOI]
  9. Vos GJ., "Management of the patient with an acute coronary syndrome using oral anticoagulation", Neth Heart J, in press
  10. Brener SJ., "Effect of prior aspirin treatment on patients with acute coronary syndromes: insights from the PROSPECT study", J Invasive Cardiol, in press
  11. Johnson SG., "Financial analysis of CYP2C19 genotyping in patients receiving dual antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention", J Manag Care Spec Pharm, 21(7), pp.552~557 (2015)
  12. Wei YQ., "Cytochrome P450 CYP 2C19*2 Associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome", PLoS One, 10(7), pp.1~8 (2015)
  13. Kim IS., "The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome", J Thromb Haemost, 7(5), pp.897~899 (2009)
  14. Rollini F., "The GRAVITAS study", G Ital Cardiol, 13(1), pp.1~5 (2012)
  15. Bavishi C., "Meta-analysis of comparison of the newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-Elevation acute coronary syndrome", Am J Cardiol, in press
  16. De Servi S., "Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-STelevation myocardial infarction : an analysis from the TRITON-TIMI 38 trial", Eur Heart J Acute Cardiovasc Care, 3(4), pp.363~372 (2014)
  17. Patel MR., "Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel : Data from the PLATO Trial", Eur J Prev Cardiol, 22(6), pp.734~742 (2015)
  18. Kang HJ., "Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome : a retrospective analysis from the platelet inhibition and patient outcomes(PLATO)trial", Am Heart J, 169(6), pp.899~905 (2015)
  19. Páramo JA, "New era in antiplatelet therapy based on results from recent clinical trials", Med Clin, 137(11), pp.504~508 (2011)
  20. Gandhi S., "Increased uptake of guideline-recommended oral antiplatelet therapy : insights from the Canadian acute coronary syndrome reflective", Can J Cardiol, 30(12), pp.1725~1731 (2014)
  21. Huber K., "Differences between ACC", AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes, 2013, pp.110(1), 11~13
  22. "AmericanHeartAssociation"[URL]
  23. "European Society of Cardiology"[URL]
  24. 우종신, "급성 관동맥 증후군 치료의 최신 지견", 대한내과학회지, 76(6), pp.661~676 (2009), 대한내과학회
  25. "Korea Society of Interventional Cardiology"[URL]
  26. O’Gara PT, "2013 ACCF", AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation, J Am Coll Cardiol, pp.2013, 61(4)[DOI]
  27. Kushner FG., "2009 Focused updates : ACC", AHA guidelines for the management of patients with ST-elevation myocardial infarction(updating the 2004 guideline and 2007 focused update)and ACC, SCAI guidelines on percutaneous coronary intervention(updating the 2005 guideline and 2007 focused update), pp.J Am Coll Cardiol, 2009[DOI]
  28. Jneid H., "2012 ACCF", AHA focused update of the guideline for the management of patients with unstable angina, American heart association task force on practice guidelines, pp.J Am Coll Cardiol, 2012[DOI]
  29. Anderson JL, "2011 ACCF", AHA focused update incorporated into the ACC, non-ST-elevation myocardial infarction: a report of the American college of cardiology foundation, pp.American heart association task force on practice guidelines, Circulation[DOI]
  30. Steg G., "ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation", Eur Heart J, 33(20), pp.2569~2619 (2012)
  31. Hamm W., "ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : the task force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European society of cardiology(ESC)", Eur Heart J, 32(23), pp.2999~3054 (2011)
  32. Krumholz HM., "ACC", AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction : a report of the American college of cardiology, Circulation, pp.2006, 113(5)[DOI]
  33. Krumholz HM., "ACC", AHA 2008 performance measures for sdults with ST-elevation and non-ST-elevation myocardial infarction : a report of the American college of cardiology, Circulation, pp.2008, 118(24)[DOI]
  34. Amsterdam EA, "2014 AHA", ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of cardiology, J Am Coll Cardiol, pp.2014, 62(24)[DOI]
  35. Kander T., "Platelet aggregation and clot formation in comatose survivors of cardiac arrest treated with induced hypothermia and dual platelet inhibition with aspirin and ticagrelor; a prospective observational study", Crit Care, 18(5), pp.495~ (2014)
  36. Kander T., "Temperature effects on haemostasis in whole blood from ticagrelor-and aspirin-treated patients with acute coronary syndrome", Scand J Clin Lab Invest, 75(1), pp.27~35 (2015)
  37. Berger JS, "Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes", Am J Cardiol, 112(5), pp.737~745 (2013)
  38. Xian Y., "Association of discharge aspirin dose with outcomes after acute myocardial infarction : insights from the treatment with ADP receptor inhibitors : longitudinal assessment of treatment patterns and events after acute coronary syndrome(TRANSLATE-ACS)Study", Circulation, 132(3), pp.174~181 (2015)
  39. Serebruany VL., "The differences between the guidelines of the European society of cardiology and the American college of cardiology", American heart association for oral P2Y12 inhibitor therapy in the management of patients with acute coronary syndromes, 2013, pp.53(7), 70~77
  40. Wouter JJ., "Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation : beyond clopidogrel", Curr Med Res Opin, 28(2), pp.203~211 (2012)
  41. Rahman A., "New oral anticoagulants and perioperative management of anticoagulant", antiplatelet agents, 2014, pp.43(12), 861~866
  42. Htun WW., "Ticagrelor : the first novel reversible P2Y(12)inhibitor", Expert Opin Pharmacother, 14(2), pp.237~245 (2013)
  43. Serebruany VL., "Viewpoint : mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes", Thromb Haemost, 110(1), pp.5~10 (2013)
  44. Linn CE., "Role of CYP450 in antiplatelet therapy : considerations for patients at risk for further cardiovascular or cerebrovascular problems", J Pharm Technol, 29(2), pp.72~77 (2013)
  45. Caldeira D., "Dyspnea and reversibility profile of P2Y antagonists : systematic review of new antiplatelet drugs", Am J Cardiovasc Drugs, 14(4), pp.303~311 (2014)
  46. Kazi. DS., "Cost-effectiveness of genotypeguided and dual antiplatelet therapies in acute coronary syndrome", Ann Inter Med, 160(4), pp.221~232 (2014)
  47. Yamwong S., "Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand", Health Econ Rev, 4(1), pp.17~ (2014)
  48. Cutlip DE., "Beyond restenosis : five-year clinical outcomes from second-generation coronary stent trials", Circulation, 110(10), pp.1226~1230 (2004)
  49. Bahler CK., "Second-generation trabecular meshwork bypass stent(iStent inject)increases outflow facility in cultured human anterior segments", Am J Ophthalmol, 153(6), pp.1206~1213 (2012)
  50. Colombo A., "Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy : the SECURITY randomized clinical trial", J Am Coll Cardiol, 64(20), pp.2086~2097 (2014)
  51. Alexopoulos D., "Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis", Am J Kidney Dis, 60(2), pp.332~333 (2012)
  52. Norgard. NB., "Clopidogrel, prasugrel, or ticagrelor? A practical guide to use of antiplatelet agents in patients with acute coronary syndromes", Postgrad Med, 125(4), pp.91~102 (2013)
  53. "Ticagrelor(Brilinta)-better than clopidogrel(Plavix)?", Med Lett Drugs Ther, 53(1372), pp.69~70 (2011)
  54. Rafeedheen R., "Novel antiplatelet agents in cardiovascular medicine", Curr Treat Options Cardiovasc Med, 17(6), pp.383~ (2015)
  55. "Guideline for pharmacotherapy of anti-platelet agent for acute coronary syndrome" (2012), Korea Society of Interventional Cardiology
  56. Sorich MJ., "CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel : a meta-analysis", Circ Cardiovasc Genet, 7(6), pp.895~902 (2014)
  57. Oh IY., "Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents", Heart, 98(2), pp.139~144 (2012)

관련 논문AI추천

경피적 관상동맥 중재 시술 후 이중 항혈소판 치료를 받는 환자에서 aspirin 병용 약제의 종류에 따른 심혈관계 사건 발생률 비교금민정, 김재송, 김혜원, 손가영, 손은선한국병원약사회 · 병원약사회지2017 · 제34권 제3호경피적 관상동맥 중재술 시행 후 이중항혈소판요법 중인 비ST분절 상승 심근경색증 환자에서 Clopidogrel과 Ticagrelor의 효과 및 안전성 비교고종희, 금민정, 김수현, 류정현, 손은선, 유윤미한국병원약사회 · 병원약사회지2025 · 제42권 제1호The current status and outcomes of in-hospital P2Y12 receptor inhibitor switching in Korean patients with acute myocardial infarction윤정한, Chong Jin Kim, Dong-Joo Choi, Doo Il Kim, Hyeon-Cheol Gwon, Hyo-Soo Kim, Hyun Kuk Kim, Hyun Yi Kook, In-Whan Seong, Jei Keon Chae, Jin-Yong Hwang, Jong Seon Park, Keun-Ho Park, Ki-Bae Seung, Kwang Soo Cha, Myeong Chan Cho, Myung Ho Jeong, Seok Kyu Oh, Seung-Ho Hur, Seung-Jae Joo, Seung Woon Rha, Shung Chull Chae, Sung Soo Kim, Tae Hoon Ahn, Young-Jae Ki, Youngkeun Ahn대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제2호경피적 관상동맥 중재술을 시행한 급성 관상동맥 증후군 환자에서 Ticagrelor와 Clopidogrel의 유효성과 안전성 비교양사미, 이상은, 이세은, 최지영, 한혜원한국병원약사회 · 병원약사회지2025 · 제42권 제3호관상동맥 약물 용출 스텐트 삽입 후 항혈소판제제 3제요법과 2제요법의 임상적 효과 비교김정태, 예경남, 이숙향한국임상약학회 · 한국임상약학회지2012 · 제22권 제2호혈소판 약물 반응검사를 토대로 한 항혈소판제 치료방침의 효과성 평가: 체계적 문헌고찰서재경, 이현아한국보건의료기술평가학회 · 보건의료기술평가2024 · 제12권 제1호

이 간행물의 다른 논문 (9건)

제 2형 당뇨병 환자의 유방암 발생 위험 및 사망률에 대한 메트포민의 영향: 체계적 문헌고찰 및 메타분석천부순pp. 131-137내과계 중환자실 약료 서비스 도입과 약물상호작용 모니터링최경숙, 이정연, 이광섭, 최재희pp. 138-144노인 입원 환자의 비암성 통증에 대한 약물 처방 현황허유정, 이유정, 최은옥, 이경주, 남기남, 김범해, 성새라pp. 145-150항암치료를 받는 미만성거대비세포 림프종 환자에서 페그필그라스팀에 대한 효용성 평가민명숙, 방준석, 이영미, 김정미, 정희원pp. 151-158상급종합병원 근처의 한 지역약국 처방전 분석에 의한 노인 환자의 다약제복용과 약제비용 및 잠재적으로 부적절한 약물사용 관련 위험인자김아람, 이정연, 김홍아pp. 159-165
원문 보기